Safety review — page 3
A review of harms, in which the absence of an event in a trial of conventional size is treated as uninformative rather than as reassurance.
Reviews
-
In the population defined for cognitive performance and neuroprotection, what is the incidence of adverse events leading to discontinuation with Semax compared with its comparator?
Very low11 Jan 2025 -
In the population defined for primary mitochondrial myopathy and bioenergetic disorders, what is the incidence of adverse events leading to discontinuation with SS-31 (elamipretide) compared with its comparator?
Moderate14 May 2025 -
In the population defined for hiv-associated lipodystrophy and excess visceral adiposity, what is the incidence of adverse events leading to discontinuation with Tesamorelin compared with its comparator?
Moderate08 Dec 2024 -
In the population defined for atherosclerotic cardiovascular disease and cardiovascular risk reduction, what is the incidence of adverse events leading to discontinuation with Tirzepatide compared with its comparator?
Moderate22 May 2026 -
In the population defined for obstructive sleep apnoea with obesity, what is the incidence of adverse events leading to discontinuation with Tirzepatide compared with its comparator?
High27 Jun 2025
page 3 of 3